Athena Athena

X
[{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Lynk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals and Simcere Announced Strategic Commercialization Partnership upon Novel JAK1 Inhibitor LNK01001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$14.0 million","newsHeadline":"COSELA\u00ae (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$30.0 million","newsHeadline":"Simcere and Idorsia Enter Into a Licensing Agreement for Daridorexant in China","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Sleep","graph2":"Approved"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II\/III Clinical Trial of Simcere's 3CL-Targeting Anti-SARS-COV-2 Drug Candidate Complete All Patients Enrollment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA\u00ae (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Connect Biopharma","pharmaFlowCategory":"D","amount":"$141.0 million","upfrontCash":"$21.0 million","newsHeadline":"Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Findings of a Phase III Clinical Study of Sanbexin\u00ae Sublingual Tablets Published in JAMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Jiangsu Simcere Pharmaceutical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.

            Lead Product(s): Edaravone,Dexborneol

            Therapeutic Area: Neurology Product Name: Sanbexin

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Neurodawn Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 20, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Simcere will develop and commercialize Connect Biopharma’s CBP-201 (rademikibart), a human monoclonal antibody against IL-4Rα, in Greater China.

            Lead Product(s): Rademikibart

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Connect Biopharma

            Deal Size: $141.0 million Upfront Cash: $21.0 million

            Deal Type: Licensing Agreement November 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims to establish a mutually beneficial partnership that will advance scientific research and create new treatment options for patients with cancer, autoimmune and CNS diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Mass General Brigham

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, MSD will supply KEYTRUDA and collaborate with Simcere to evaluate the combination of SIM0235, a potential first-in-class humanized anti-TNFR2 mAb, and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors and CTCL.

            Lead Product(s): SIM0235,Pembrolizumab

            Therapeutic Area: Oncology Product Name: SIM0235

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate SSD8432 and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

            Lead Product(s): SSD8432,Ritonavir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Xiannuoxin

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Simcere will be granted an exclusive right to develop and commercialize daridorexant (ACT-541468) in the Greater China region (Mainland China, Hong Kong, and Macau), one of the world's largest pharmaceutical markets.

            Lead Product(s): Daridorexant

            Therapeutic Area: Sleep Product Name: ACT-541468

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Idorsia Pharmaceuticals

            Deal Size: $50.0 million Upfront Cash: $30.0 million

            Deal Type: Licensing Agreement November 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SIM0237 is an anti-PD-L1 monoclonal antibody fused with potency reduced IL-15/IL-15Rα sushi domain developed in-house by utilizing the Simcere's protein engineering platform. It can block the PD-1/PD-L1 immunosuppressive pathway via binding to PD-L1.

            Lead Product(s): SIM0237

            Therapeutic Area: Oncology Product Name: SIM0237

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            COSELA® (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.

            Lead Product(s): Trilaciclib

            Therapeutic Area: Oncology Product Name: Cosela

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: G1 Therapeutics, Inc

            Deal Size: $170.0 million Upfront Cash: $14.0 million

            Deal Type: Licensing Agreement July 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SIM0417 has shown broad-spectrum antiviral activity, good in vivo pharmacokinetic properties, and safety in pre-clinical studies. It is a highly active, low toxicity, orally administrable small molecule anti-SARS-CoV-2 drug candidate.

            Lead Product(s): SIM0417

            Therapeutic Area: Infections and Infectious Diseases Product Name: SIM0417

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            First-in-class (FIC) novel myelo-protective drug trilaciclib targeting large Chinese patient population receiving chemotherapy, the product has the potential for delivering significant patient impact and commercial success.

            Lead Product(s): SIM0417

            Therapeutic Area: Infections and Infectious Diseases Product Name: SIM0417

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY